News | July 20, 2023
M&A activity of pharma CMOs will continue despite challenging borrowing environment, says GlobalData
CMOs showed an increasing reluctance to take on debt in 2022
CMOs showed an increasing reluctance to take on debt in 2022
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene therapies at all stages of development.
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
Subscribe To Our Newsletter & Stay Updated
